Severe enterocolitis secondary to ipilimumab and nivolumab with an excellent response to a single dose of infliximab.

Luque Carmona, Ana MaríaOntanilla-Clavijo, GuillermoLeo Carnerero, Eduardo2023-02-092023-02-0920201130-0108http://hdl.handle.net/10668/16420Immunotherapy is gaining significance in the management of oncological disease. It has demonstrated high levels of efficacy, though it also has hitherto unknown side effects, such as colitis. We present the first case of immune checkpoint inhibitor colitis (nivolumab+ipilimumab) refractory to corticoids treated in our hospital.enColitisEnterocolitisHumansInfliximabIpilimumabNivolumabSevere enterocolitis secondary to ipilimumab and nivolumab with an excellent response to a single dose of infliximab.research article33054275open access10.17235/reed.2020.6886/2020https://doi.org/10.17235/reed.2020.6886/2020